Interim Report, Q2 2021

BioPorto

August 18, 2021

Forward-Looking Statements

References herein to this presentation shall mean and include this document, any oral presentation accompanying this document provided by BioPorto A/S (the "Company") and any further information that may be made available in connection with the subject matter contained herein. By viewing or receiving or reading this presentation or attending any meeting where this presentation is made, you agree to be bound by the limitations, qualifications and restrictions set out below:

This presentation contains forward-looking statements. Words such as "believe", "expect", "may", "plan", "strategy", "estimate", "target" and similar expressions identify such forward-looking statements. Statements other than historical facts included in this presentation concerning our plans, objectives, goals, future events and performance are forward-looking statements. They involve risks, uncertainties and other factors, which may cause actual results, performance and achievements to differ materially from the results discussed in the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date of this presentation.

This presentation is for information purposes only and does not constitute an offer to sell or a solicitation of any offer to buy any securities issued by BioPorto A/S (the "Company") in any jurisdiction. The information contained herein is not for distribution in the United States of America. This document does not constitute, or form part of, an offer to sell, or a solicitation of an offer to purchase, any securities in the United States. The Company's securities have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") and may not be offered or sold within the United States absent registration or pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to offer or solicit an offer to buy any securities in the Company in the United States or to make a public offering of the securities in the United States. Company securities may be sold only to qualified institutional buyers (as defined in Rule 144A under the Securities Act) in reliance on Rule 144A.

Agenda

1 Highlights from Q2 2021

2 1H 2021 financial results

3 Regulatory update

4 2021 milestones

Highlights from Q2 2021

- Revenue growth of 84% in USD on RUO sales of The NGAL Test and 118% for antibodies
- Enrollment in US clinical trial of The NGAL Test continues with added sites – interim results expected end-August
- Data collection for gRAD COVID-19 test extended into Q3 2021
- FDA dialogue initiated on EUA for The NGAL Test for COVID-19 patients
- Search for new CEO and CFO progressing
- Guidance for 2021 maintained



1H 2021
financial results

bioporto



Strong increase in antibodies & The NGAL Test in US; ROW impacted by order postponement to H2 2021

Revenue by Product Category (DKKm)



US NGAL

+68%

Increase in revenue (DKK) from RUO sales of The NGAL Test in US from Q2 2020 to Q2 2021

Antibodies

+118%

Increase in revenue (DKK) from antibodies in Q2 2021 vs. Q2 2020

1H 2021 revenue growth of 20% in USD;11% in DKK

Revenue by Quarter (DKKm)



NGAL Product Sales by Quarter (LTM, DKKm)



EBIT reflects re-initiation of clinical trial of NGAL; Strong cash position provides funding to Q2 2022

EBIT and cash position (DKKm)



- EBIT loss on par with last year – lower R&D and sales costs and expected increase in administration costs
- Solid cash position end-June 2021 of DKK 75 million to fund high level of activity on both commercial and development/regulatory into Q2 2022
- Further funding opportunities are being explored to strength BioPorto's long term financial position

New members elected to the Board of Directors; retained search for CEO and CFO in process

- In April 2021, the Board of Directors was expanded to include Don Hardison, John McDonough and Jan Leth Christensen; Torben Arnth Nielsen and Kirsten Aarup Drejer did not seek re-election

- The Board of Directors is interviewing candidates for the CEO & CFO positions and expects to appoint new members of the executive management team in the fall of 2021

Don Hardison

John McDonough

Jan Leth Christensen

Regulatory update

The NGAL Test is CE marked and available for IVD use in the European Union, Canada, S. Korea and Israel. For research use only in all other territories.

Enrollment in US NGAL study builds; interim results expected in August

Pediatric study

1 in 4 affected with AKI during hospitalization (ICU)[1]

Predict AKI Risk in an Intensive Care Setting

- Urine samples
- Predict Stage 2/3 AKI

Interim analysis

- **EARNEST data to be evaluated**
- **Sensitivity, specificity and test statistics**
- **Results of the analysis will guide finalization of study**

- Non-hospital studies have been finalized
- Enrollment of patients in the US clinical trial for The NGAL Test has progressed well in Q2 2021, but is still affected by limitations caused by COVID-19
- 12 sites are now participating, with several new joining in Q2 2021 – pace of enrollment has increased in July; more sites are being added
- In August, BioPorto will conduct an interim analysis of results. Based on expected positive findings, BioPorto will evaluate scope of enrollment to strengthen its submission to FDA

1) Kaddourah A, et al. *N Engl J Med*. 2017; 376(1):11-20.

The NGAL Test being evaluated for EUA in COVID-19 patients at risk of renal injury

- BioPorto has initiated a dialogue with FDA on potential Emergency Use Authorization (EUA) of The NGAL Test to screen COVID-19 patients for risk of renal failure
- Will base the EUA submission on key findings from an ELISA and dipstick study of NGAL which showed a negative predictive value of 97%. Samples from this study will be tested with The NGAL Test and would form the basis of the EUA
- If granted an EUA, The NGAL Test could be an important biomarker to identify COVID-19 patients at low risk of requiring renal replacement therapy, helping to optimize resource allocation in the emergency department



Generic Rapid Assay Device (gRAD) platform

BioPorto's patented Generic Rapid Assay Device (gRAD) technology is a lateral flow test development platform with no analyte-specific reagents on the strip.

Instead, labelled capture antibodies and gold nanoparticle conjugated detection antibodies form detectable complexes with the analyte in a simple preanalytical mixing step (off-strip).

Complexes are detected by the dipstick and can be evaluated both qualitatively and quantitatively with superior performance characteristics, compared to standard lateral flow assays.



Data collection for gRAD COVID-19 test continues in Q3 2021

- In Q2, BioPorto increased sensitivity of the gRAD-based SARS-CoV-2 assay, but the number of patients has been low due to a drop in COVID-19 cases
- Focus is to secure a sensitivity above 80% to strengthen the platform's potential
- Target not reached yet, but prospects are promising. Testing resources focused in Denmark in Q3 2021 on the development of the test for new SARS-CoV-2 mutations
- Goal remains to undertake CE filing and potentially submit an EUA to the FDA



Interim data for gRAD-based Sepsis test pending



- BioPorto and Rigshospitalet (DK) are co-developing a gRAD test for quantitative determination of thrombomodulin in human plasma
- Test is part of trial evaluating safety and efficacy of thrombomodulin vs. placebo in trauma patients with hemorrhagic shock-induced endotheliopathy
- BioPorto expects interim data to be available in Q3 2021 leading to a decision on the business perspectives

2021 milestones



Strong news flow expected in Q3 2021

- Interim analysis of data from The NGAL Test pediatric study
- EUA application for The NGAL Test for risk of renal injury in COVID-19 patients
- Status and update on gRAD COVID-19-test
- Interim data on gRAD Sepsis test

Targeted 2021 Milestones

- Finalize and submit FDA application for The NGAL Test in pediatrics
- Collect supplementary data to support submission of an application for The NGAL Test in adults
- Secure data for study supporting regulatory application(s) for gRAD COVID-19 rapid test
- Progress development of new rapid assays on gRAD platform
- Grow revenues by 25%

Financial projections for 2021 maintained

Revenue

Approx. DKK 30m

EBIT loss

Approx. DKK 73m

Guidance for 2021 is dependent on the global development of COVID-19. Changes to the current outlook for a gradual opening of societies and normalization of access to clinical trials at hospitals and regulatory application processes are prerequisites for the guidance above.

Financial Calendar 2021

August 18, 2021	Q2 2021 Results
November 17, 2021	Q3 2021 Results

Contact:
Peter Mørch Eriksen (CEO)
investor@bioporto.com

bioporto